123 related articles for article (PubMed ID: 22704123)
1. Gemcitabine causes telomere attrition by stabilizing TRF2.
Su CH; Chu WC; Lan KH; Li CP; Chao Y; Lin HC; Lee SD; Tsai YC; Lee WP
Eur J Cancer; 2012 Dec; 48(18):3465-74. PubMed ID: 22704123
[TBL] [Abstract][Full Text] [Related]
2. The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine.
Lee WP; Lan KH; Li CP; Chao Y; Hou MC; Lin HC; Lee SD
Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):917-928. PubMed ID: 28088627
[TBL] [Abstract][Full Text] [Related]
3. Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms.
Wu Y; Mitchell TR; Zhu XD
Mech Ageing Dev; 2008 Oct; 129(10):602-10. PubMed ID: 18812185
[TBL] [Abstract][Full Text] [Related]
4. Curcusone C induces telomeric DNA-damage response in cancer cells through inhibition of telomeric repeat factor 2.
Wang M; Cao J; Zhu JY; Qiu J; Zhang Y; Shu B; Ou TM; Tan JH; Gu LQ; Huang ZS; Yin S; Li D
Biochim Biophys Acta Proteins Proteom; 2017 Nov; 1865(11 Pt A):1372-1382. PubMed ID: 28870734
[TBL] [Abstract][Full Text] [Related]
5. XPF with mutations in its conserved nuclease domain is defective in DNA repair but functions in TRF2-mediated telomere shortening.
Wu Y; Zacal NJ; Rainbow AJ; Zhu XD
DNA Repair (Amst); 2007 Feb; 6(2):157-66. PubMed ID: 17055345
[TBL] [Abstract][Full Text] [Related]
6. Sp1 upregulates expression of TRF2 and TRF2 inhibition reduces tumorigenesis in human colorectal carcinoma cells.
Dong W; Shen R; Wang Q; Gao Y; Qi X; Jiang H; Yao J; Lin X; Wu Y; Wang L
Cancer Biol Ther; 2009 Nov; 8(22):2166-74. PubMed ID: 19783902
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic doses of hydroxyurea cause telomere dysfunction and reduce TRF2 binding to telomeres.
Snyder AR; Zhou J; Deng Z; Lieberman PM
Cancer Biol Ther; 2009 Jun; 8(12):1136-45. PubMed ID: 19363303
[TBL] [Abstract][Full Text] [Related]
8. TRF2 controls telomeric nucleosome organization in a cell cycle phase-dependent manner.
Galati A; Magdinier F; Colasanti V; Bauwens S; Pinte S; Ricordy R; Giraud-Panis MJ; Pusch MC; Savino M; Cacchione S; Gilson E
PLoS One; 2012; 7(4):e34386. PubMed ID: 22536324
[TBL] [Abstract][Full Text] [Related]
9. WRN controls formation of extrachromosomal telomeric circles and is required for TRF2DeltaB-mediated telomere shortening.
Li B; Jog SP; Reddy S; Comai L
Mol Cell Biol; 2008 Mar; 28(6):1892-904. PubMed ID: 18212065
[TBL] [Abstract][Full Text] [Related]
10. Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA.
Stagno D'Alcontres M; Mendez-Bermudez A; Foxon JL; Royle NJ; Salomoni P
J Cell Biol; 2007 Dec; 179(5):855-67. PubMed ID: 18056407
[TBL] [Abstract][Full Text] [Related]
11. ERCC1/XPF removes the 3' overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes.
Zhu XD; Niedernhofer L; Kuster B; Mann M; Hoeijmakers JH; de Lange T
Mol Cell; 2003 Dec; 12(6):1489-98. PubMed ID: 14690602
[TBL] [Abstract][Full Text] [Related]
12. Abnormal function of telomere protein TRF2 induces cell mutation and the effects of environmental tumor‑promoting factors (Review).
Wang Z; Wu X
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34278498
[TBL] [Abstract][Full Text] [Related]
13. Control of human telomere length by TRF1 and TRF2.
Smogorzewska A; van Steensel B; Bianchi A; Oelmann S; Schaefer MR; Schnapp G; de Lange T
Mol Cell Biol; 2000 Mar; 20(5):1659-68. PubMed ID: 10669743
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage.
Ballal RD; Saha T; Fan S; Haddad BR; Rosen EM
J Biol Chem; 2009 Dec; 284(52):36083-36098. PubMed ID: 19797051
[TBL] [Abstract][Full Text] [Related]
15. TRF2-tethered TIN2 can mediate telomere protection by TPP1/POT1.
Frescas D; de Lange T
Mol Cell Biol; 2014 Apr; 34(7):1349-62. PubMed ID: 24469404
[TBL] [Abstract][Full Text] [Related]
16. The telomere binding protein TRF2 induces chromatin compaction.
Baker AM; Fu Q; Hayward W; Victoria S; Pedroso IM; Lindsay SM; Fletcher TM
PLoS One; 2011 Apr; 6(4):e19124. PubMed ID: 21526145
[TBL] [Abstract][Full Text] [Related]
17. TRF2 recruits ORC through TRFH domain dimerization.
Higa M; Kushiyama T; Kurashige S; Kohmon D; Enokitani K; Iwahori S; Sugimoto N; Yoshida K; Fujita M
Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):191-201. PubMed ID: 27836746
[TBL] [Abstract][Full Text] [Related]
18. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.
Galmarini CM; Clarke ML; Falette N; Puisieux A; Mackey JR; Dumontet C
Int J Cancer; 2002 Feb; 97(4):439-45. PubMed ID: 11802204
[TBL] [Abstract][Full Text] [Related]
19. G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells.
Zhou WJ; Deng R; Zhang XY; Feng GK; Gu LQ; Zhu XF
Mol Cancer Ther; 2009 Dec; 8(12):3203-13. PubMed ID: 19996277
[TBL] [Abstract][Full Text] [Related]
20. Telomere attrition and chromosome instability via downregulation of TRF2 contributes to arsenic trioxide-induced apoptosis of human T-Cell leukemia cell line molt-4 cells.
Jiao Y; Zhang W; Liu J; Ni W; Xu W; Jin J; Qian W
Cancer Biol Ther; 2007 Aug; 6(8):1186-92. PubMed ID: 17643074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
